NRXP ▼ -5.2% - NRx Pharmaceuticals, Inc. $NRXP - NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine NRx Pharmaceuticals shares fell 5.2% after the company announced that the FDA revised its previous major amendment to the company's preservative-free ketamine application down to a minor amendment. The downward reclassification of the regulatory feedback suggests a less comprehensive review process ahead, which may have disappointed investors anticipating a more substantive pathway forward for the drug candidate. 15-SEP-2026 03:11 PM ET